About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 523761, 15 pages
http://dx.doi.org/10.1155/2013/523761
Research Article

Antileukotriene Reverts the Early Effects of Inflammatory Response of Distal Parenchyma in Experimental Chronic Allergic Inflammation

1Medicine Department, School of Medicine, University of São Paulo(USP), 01246-903 São Paulo, SP, Brazil
2Biological Science Department, Universidade Federal de São Paulo(UNIFESP), 09972-270 Diadema, SP, Brazil

Received 2 May 2013; Revised 23 July 2013; Accepted 24 July 2013

Academic Editor: Alexandre Paula Rogerio

Copyright © 2013 Nathália Brandão Gobbato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, World Health Report 2000 Making a Difference, WHO, Geneve, Switzerland, 2000.
  2. A. B. Kay, “The role of eosinophils in the pathogenesis of asthma,” Trends in Molecular Medicine, vol. 11, no. 4, pp. 148–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Bousquet, “Workshop summary: relating inflammatory changes in asthma to clinical status,” Respiratory Medicine, vol. 94, pp. S32–S33, 2000. View at Scopus
  4. R. M. Pascual and S. P. Peters, “Airway remodeling contributes to the progressive loss of lung function in asthma: an overview,” Journal of Allergy and Clinical Immunology, vol. 116, no. 3, pp. 477–486, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. K. L. Veraldi, B. T. Gibson, H. Yasuoka et al., “Role of insulin-like growth factor binding protein-3 in allergic airway remodeling,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 7, pp. 611–617, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. D. C. Hocking, “Fibronectin matrix deposition and cell contractility: implications for airway remodeling in asthma,” Chest, vol. 122, no. 6, pp. 275S–278S, 2002. View at Scopus
  7. M. R. Edwards, N. W. Bartlett, D. Clarke, M. Birrell, M. Belvisi, and S. L. Johnston, “Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease,” Pharmacology and Therapeutics, vol. 121, no. 1, pp. 1–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Angeli, C. M. Prado, D. G. Xisto et al., “Effects of chronic L-NAME treatment lung tissue mechanics, eosinophilic and extracellular matrix responses induced by chronic pulmonary inflammation,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 294, no. 6, pp. L1197–L1205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Lanças, D. I. Kasahara, C. M. Prado, I. F. L. C. Tibério, M. A. Martins, and M. Dolhnikoff, “Comparison of early and late responses to antigen of sensitized guinea pig parenchymal lung strips,” Journal of Applied Physiology, vol. 100, no. 5, pp. 1610–1616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. S. Nakashima, C. M. Prado, T. Lanças et al., “Oral tolerance attenuates changes in in vitro lung tissue mechanics and extracellular matrix remodeling induced by chronic allergic inflammation in guinea pigs,” Journal of Applied Physiology, vol. 104, no. 6, pp. 1778–1785, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Bjermer, “History and future perspectives of treating asthma as a systemic and small airways disease,” Respiratory Medicine, vol. 95, no. 9, pp. 703–719, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Dolhnikoff, L. F. F. da Silva, B. B. de Araujo et al., “The outer wall of small airways is a major site of remodeling in fatal asthma,” Journal of Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1090–1097, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. E. A. Leick-Maldonado, F. U. Kay, M. C. Leonhardt et al., “Comparison of glucocorticoid and cysteinyl leukotriene receptor antagonist treatments in an experimental model of chronic airway inflammation in guinea-pigs,” Clinical and Experimental Allergy, vol. 34, no. 1, pp. 145–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. I. F. L. C. Tibério, G. M. G. Turco, E. A. Leick-Maldonado et al., “Effects of neurokinin depletion on airway inflammation induced by chronic antigen exposure,” American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 5, pp. 1739–1747, 1997. View at Scopus
  15. C. A. Burgess, B. K. McCandless, J. A. Cooper, and A. B. Malik, “Leukotriene B4 increases pulmonary transvascular filtration by a neutrophil-independent mechanism,” Journal of Applied Physiology, vol. 68, no. 3, pp. 1260–1264, 1990. View at Scopus
  16. W. W. Busse, “Leukotrienes and inflammation,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 6, pp. S210–S213, 1998. View at Publisher · View at Google Scholar
  17. S. Jancar, “Imunidade natural e inflamação,” in Imunologia Básica, V. Calich and C. Vaz, Eds., pp. 11–30, Revinter, São Paulo, Brazil, 2001.
  18. T. J. Vandermeer, M. J. Menconi, B. P. O'Sullivan et al., “Acute lung injury in endotoxemic pigs: role of leukotriene B4,” Journal of Applied Physiology, vol. 78, no. 3, pp. 1121–1131, 1995. View at Scopus
  19. S. Joos, A. Miksch, J. Szecsenyi et al., “Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review,” Thorax, vol. 63, no. 5, pp. 453–462, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Stelmach, J. Jerzynska, and P. Kuna, “A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma,” Journal of Allergy and Clinical Immunology, vol. 109, no. 2, pp. 257–263, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. S. J. McMillan, G. Xanthou, and C. M. Lloyd, “Therapeutic administration of Budesonide ameliorates allergen-induced airway remodelling,” Clinical and Experimental Allergy, vol. 35, no. 3, pp. 388–396, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. R. Bonsignore, S. La Grutta, F. Cibella et al., “Effects of exercise training and montelukast in children with mild asthma,” Medicine and Science in Sports and Exercise, vol. 40, no. 3, pp. 405–412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Jartti, “Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma?” European Journal of Pediatrics, vol. 167, no. 7, pp. 731–736, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. F. C. R. Souza, N. B. Gobbato, G. R. Maciel et al., “Effects of corticosteroid, montelukast and iNOS inhibition on distal lung with chronic inflammation,” Respiratory Physiology & Neurobiology, vol. 185, no. 2, pp. 435–445, 2013. View at Publisher · View at Google Scholar
  25. E. Goleva, P. J. Hauk, J. Boquniewicz, R. J. Martin, and D. Y. Leung, “Airway remodeling and lack of bronchodilator response in steroid-resistant asthma,” The Journal of Allergy and Clinical Immunology, vol. 120, no. 5, pp. 1065–1072, 2007. View at Publisher · View at Google Scholar
  26. National Institutes of Health/Health Research Extension Act of 1985, “Animals in Research, U.S. Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training Public Health Service Policy on Humane Care and Use of Laboratory Animals,” Public Law 99-158, November 1985, http://grants.nih.gov/grants/olaw/references/phspol.htm#USGovPrinciples.
  27. C. M. Prado, E. A. Leick-Maldonado, V. Arata, D. I. Kasahara, M. A. Martins, and I. F. L. C. Tibério, “Neurokinins and inflammatory cell iNOS expression in guinea pigs with chronic allergic airway inflammation,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 288, no. 4, pp. L741–L748, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. A. J. Seco, M. E. Salgueiro, M. A. Villanueva, and G. Manso, “Treatment with high doses of terbutaline induces β-adrenergic desensitization of guinea pig trachea not prevented by the addition of dexamethasone,” Respiration, vol. 67, no. 5, pp. 559–564, 2000. View at Scopus
  29. S. S. Possa, H. T. Charafeddine, R. F. Righetti et al., “Rho-kinase inhibition attenuates airway responsiveness, inflammation, matrix remodeling, and oxidative stress activation induced by chronic inflammation,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 303, no. 11, pp. L939–L952, 2012. View at Publisher · View at Google Scholar
  30. C. M. Starling, C. M. Prado, E. A. Leick-Maldonado et al., “Inducible nitric oxide synthase inhibition attenuates lung tissue responsiveness and remodeling in a model of chronic pulmonary inflammation in guinea pigs,” Respiratory Physiology and Neurobiology, vol. 165, no. 2-3, pp. 185–194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. L. G. Luna, AFIP Manual of Histologic Staining Methods, McGraw Hill, New York, NY, USA, 1986.
  32. J. H. Zar, Biostatistical Analysis, Prentice-Hall, Englewood Cliffs, NJ, USA, 2nd edition, 1984.
  33. L. Smith, “Comparative efficacy of inhaled corticosteroids and antileukotriene drugs in asthma,” BioDrugs, vol. 15, no. 4, pp. 239–249, 2001. View at Scopus
  34. B. Knorr, L. M. Franchi, H. Bisgaard et al., “Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years,” Pediatrics, vol. 108, no. 3, p. E48, 2001. View at Scopus
  35. J. S. Kelloway, R. A. Wyatt, and S. A. Adlis, “Comparison of patients' compliance with prescribed oral and inhaled asthma medications,” Archives of Internal Medicine, vol. 154, no. 12, pp. 1349–1352, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Tsurufuji, A. Kurihara, and F. Ojima, “Mechanisms of anti-inflammatory action of dexamethasone: blockade by hydrocortisone mesylate and actinomycin D of the inhibitory effect of dexamethasone on leukocyte infiltration in inflammatory sites,” Journal of Pharmacology and Experimental Therapeutics, vol. 229, no. 1, pp. 237–243, 1984. View at Scopus
  37. J. Liu, M. Zhang, C. Niu et al., “Dexamethasone inhibits repair of human airway epithelial cells mediated by glucocorticoid-induced leucine zipper (GILZ),” PLoS One, vol. 8, no. 4, Article ID e60705, 2013. View at Publisher · View at Google Scholar
  38. M. Peters-Golden and W. R. Henderson Jr., “Mechanisms of disease: leukotrienes,” The New England Journal of Medicine, vol. 357, no. 18, pp. 1798–1854, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. R. C. Gualano, R. Vlahos, and G. P. Anderson, “What is the contribution of respiratory viruses and lung proteases to airway remodelling in asthma and chronic obstructive pulmonary disease?” Pulmonary Pharmacology and Therapeutics, vol. 19, no. 1, pp. 18–23, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Kondo, T. Katsunuma, Y. Odajima, and A. Morikawa, “A randomized open-label comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children,” Allergology International, vol. 55, no. 3, pp. 287–293, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Mechiche, E. Naline, L. Candenas et al., “Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites,” Clinical and Experimental Allergy, vol. 33, no. 7, pp. 887–894, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention Program, Publication no. 02-3659, Department of Health, Education, and Welfare, National Heart, Lung, and Blood Institute/World Health Organization, Washington, DC, USA, 2009, http://www.ginasthma.org/pdf/GINA_Report_2010.pdf.
  43. W. W. Busse, “Inflammation in asthma: the cornerstone of the disease and target of therapy,” Journal of Allergy and Clinical Immunology, vol. 102, no. 4, pp. S17–S22, 1998. View at Scopus
  44. J. C. Gutierrez-Ramos, C. Lloyd, and J. A. Gonzalo, “Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions,” Immunology Today, vol. 20, no. 11, pp. 500–504, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. M.-C. Seminario and G. J. Gleich, “The role of eosinophils in the pathogenesis of asthma,” Current Opinion in Immunology, vol. 6, no. 6, pp. 860–864, 1994. View at Publisher · View at Google Scholar · View at Scopus
  46. L. M. Teran, “CCL chemokines and asthma,” Immunology Today, vol. 21, no. 5, pp. 235–242, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Alam, “Chemokines in allergic inflammation,” Journal of Allergy and Clinical Immunology, vol. 99, no. 3, pp. 273–277, 1997. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Uguccioni, C. R. Mackay, B. Ochensberger et al., “High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines,” Journal of Clinical Investigation, vol. 100, no. 5, pp. 1137–1143, 1997. View at Scopus
  49. L. M. Teran, Y. Ledesma-Soto, S. Krengel, and D. Lezcano-Meza, “Eotaxinas em asma bronquial y poliposis nasal,” Gaceta Médica de México, vol. 142, no. 2, pp. 139–144, 2006.
  50. Z. Diamant and A. P. Sampson, “Anti-inflammatory mechanisms of leukotriene modulators,” Clinical and Experimental Allergy, vol. 29, no. 11, pp. 1449–1453, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Pizzichini, J. A. Leff, T. F. Reiss et al., “Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial,” European Respiratory Journal, vol. 14, no. 1, pp. 12–18, 1999. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Ying, D. S. Robinson, Q. Meng et al., “Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells,” European Journal of Immunology, vol. 27, no. 12, pp. 3507–3516, 1997. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Mattoli, M. A. Stacey, G. Sun, A. Bellini, and M. Marini, “Eotaxin expression and eosinophilic inflammation in asthma,” Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 299–301, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Y. Wu, S. C. Chik, A. W. Chan, Z. Li, K. W. Tsang, and W. Li, “Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma,” Clinical and Experimental Allergy, vol. 33, no. 3, pp. 359–366, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Nagata, K. Saito, I. Kikuchi, K. Hagiwara, and M. Kanazawa, “Effect of the cysteinyl leukotriene antagonist pranlukast on transendothelial migration of eosinophils,” International Archives of Allergy and Immunology, vol. 137, no. 1, pp. 2–6, 2005. View at Publisher · View at Google Scholar
  56. J.-A. Gonzalo, C. M. Lloyd, D. Wen et al., “The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness,” Journal of Experimental Medicine, vol. 188, no. 1, pp. 157–167, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. J. J. Tomasek, G. Gabbiani, B. Hinz, C. Chaponnier, and R. A. Brown, “Myofibroblasts and mechano: regulation of connective tissue remodelling,” Nature Reviews Molecular Cell Biology, vol. 3, no. 5, pp. 349–363, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. S. R. Singh and I. P. Hall, “Airway myofibroblasts and their relationship with airway myocytes and fibroblasts,” Proceedings of the American Thoracic Society, vol. 5, no. 1, pp. 127–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. M. N. Sheppard and N. K. Harrison, “Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis,” Thorax, vol. 47, no. 12, pp. 1064–1074, 1992. View at Scopus
  60. F. M. Spoelstra, D. S. Postma, and H. F. Kauffman, “Mutual activation of pulmonary fibroblasts and eosinophils, and modulation by drugs in relation to asthma,” Clinical and Experimental Allergy, vol. 31, no. 6, pp. 808–816, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. Y.-H. Nam, S.-K. Lee, D. Sammut, D. E. Davies, and P. H. Howarth, “Preliminary study of the cellular characteristics of primary bronchial fibroblasts in patients with asthma: expression of α-smooth muscle actin, fibronectin containing extra type III domain a, and smoothelin,” Journal of Investigational Allergology and Clinical Immunology, vol. 22, no. 1, pp. 20–27, 2012. View at Scopus
  62. G. Gabbiani, “The biology of the myofibroblast,” Kidney International, vol. 41, no. 3, pp. 530–532, 1992. View at Scopus
  63. R. Bucala, L. A. Spiegel, J. Chesney, M. Hogan, and A. Cerami, “Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair,” Molecular Medicine, vol. 1, no. 1, pp. 71–81, 1994. View at Scopus
  64. R. Pankov and K. M. Yamada, “Fibronectin at a glance,” Journal of Cell Science, vol. 115, no. 20, pp. 3861–3863, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Serini, M.-L. Bochaton-Piallat, P. Ropraz et al., “The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1,” Journal of Cell Biology, vol. 142, no. 3, pp. 873–881, 1998. View at Publisher · View at Google Scholar · View at Scopus
  66. A. F. Muro, A. K. Chauhan, S. Gajovic et al., “Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan,” Journal of Cell Biology, vol. 162, no. 1, pp. 149–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Kato, T. Kohyama, H. Okazaki et al., “Leukotriene D4 potentiates fibronectin-induced migration of human lung fibroblasts,” Clinical Immunology, vol. 117, no. 2, pp. 177–181, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Tokuriki, Y. Ohshima, A. Yamada, N. Ohta, H. Tsukahara, and M. Mayumi, “Leukotriene D4 enhances the function of endothelin-1-primed fibroblasts,” Clinical Immunology, vol. 125, no. 1, pp. 88–94, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. S. T. Holgate, M. Peters-Golden, R. A. Panettieri et al., “Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling,” Journal of Allergy and Clinical Immunology, vol. 111, supplement 1, pp. S18–S36, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. N. Khalil and A. H. Greenberg, “The role of TGF-beta in pulmonary fibrosis,” Ciba Foundation Symposium, vol. 157, pp. 194–207, 1991. View at Scopus
  71. J. I. Jones and D. R. Clemmons, “Insulin-like growth factors and their binding proteins: biological actions,” Endocrine Reviews, vol. 16, no. 1, pp. 3–34, 1995. View at Scopus
  72. M. H. Muz, F. Deveci, Y. Bulut, N. Ilhan, H. Yekeler, and T. Turgut, “The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model,” Experimental and Molecular Medicine, vol. 38, no. 2, pp. 109–118, 2006. View at Scopus
  73. W. R. Henderson Jr., L. Tang, S. Chu et al., “A role for cysteinylleukotrienesin airway remodeling in a mouse asthma model,” American Journal of Respiratory and Critical Care Medicine, vol. 65, no. 1, pp. 108–116, 2002.
  74. R. Rajah, L. Katz, S. Nunn, P. Solberg, T. Beers, and P. Cohen, “Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth,” Cytokine and Growth Factor Reviews, vol. 6, no. 2–4, pp. 273–284, 1995. View at Scopus
  75. R. Rajah, S. E. Nunn, D. J. Herrick, M. M. Grunstein, and P. Cohen, “Leukotriene D4 induces MMP-1, which functions as an IGFBP protease in human airway smooth muscle cells,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 271, no. 6, part 1, pp. L1014–L1022, 1996. View at Scopus
  76. M. Hoshino, Y. Nakamura, J. J. Sim et al., “Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma,” Clinical and Experimental Allergy, vol. 28, no. 5, pp. 568–577, 1998. View at Publisher · View at Google Scholar · View at Scopus
  77. A. R. Tanner and L. W. Powell, “Corticosteroids in liver disease: possible mechanisms of action, pharmacology, and rational use,” Gut, vol. 20, no. 12, pp. 1109–1124, 1979. View at Scopus
  78. G. Gayan-Ramirez, F. Vanderhoydonc, G. Verhoeven, and M. Decramer, “Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 1, pp. 283–289, 1999. View at Scopus
  79. J. C. Schwander, C. Hauri, J. Zapf, and E. R. Froesch, “Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status,” Endocrinology, vol. 113, no. 1, pp. 297–305, 1983. View at Scopus
  80. A. S. Baldwin Jr., “Series introduction: the transcription factor NF-kappaB and human disease,” The Journal of Clinical Investigation, vol. 107, pp. 3–6, 2001. View at Publisher · View at Google Scholar
  81. C.-C. Lin, C.-Y. Lin, and H.-Y. Ma, “Pulmonary function changes and increased Th-2 cytokine expression and nuclear factor kB activation in the lung after sensitization and allergen challenge in brown Norway rats,” Immunology Letters, vol. 73, no. 1, pp. 57–64, 2000. View at Scopus
  82. F. Aktan, “iNOS-mediated nitric oxide production and its regulation,” Life Sciences, vol. 75, no. 6, pp. 639–653, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. D. H. Broide, “Immunologic and inflammatory mechanisms that drive asthma progression to remodeling,” Journal of Allergy and Clinical Immunology, vol. 121, no. 3, pp. 560–570, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. E. S. Silverman, S. B. Liggett, E. W. Gelfand et al., “The pharmacogenetics of asthma: a candidate gene approach,” Pharmacogenomics Journal, vol. 1, no. 1, pp. 27–37, 2001. View at Scopus
  85. N. Charokopos, N. Apostolopoulos, M. Kalapodi, M. Leotsinidis, N. Karamanos, and A. Mouzaki, “Bronchial asthma, chronic obstructive pulmonary disease and NF-κB,” Current Medicinal Chemistry, vol. 16, no. 7, pp. 867–883, 2009. View at Publisher · View at Google Scholar · View at Scopus